DSIP: where it stands with the FDA, and what it costs
No FDA-approved drug contains it.
Go to clinicLowest per monthDSIP injection (5mg)
FormBlends · $161.10/mo
Go to clinicLowest at a clinic we link toDSIP injection (5mg)
Pepti · $249/mo (≈ $267 per 30 days with its fees)
Where DSIP stands today
No FDA-approved drug contains DSIP (emideltide). FDA had it in 503A Category 2 from September 2023 until April 22, 2026 (nominations withdrawn). On July 24, 2026 the advisory committee voted 6-7 (1 abstention, per law-firm reports) against listing it, the only one of seven peptides that day it did not recommend. HHS left it out of its October 2026 interim policy. It is not on the 503A or 503B bulks list and is in no category.
For pharmacies compounding one patient's prescription (section 503A)
Not in any 503A category and not on the 503A bulks list. Removed from Category 2 on April 22, 2026 (nominations withdrawn); the advisory committee voted 6-7 against listing it (July 24, 2026, per law-firm reports); excluded from HHS's Oct 2026 interim policy.
“Bulk drug substances nominated but withdrawn ... Emideltide (DSIP) Compounded drugs containing emideltide may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization.”
““Emideltide (DSIP)” has been removed from category 2 because the nominations were withdrawn by the nominators.”
HHS's list of six does not include emideltide
“Appendix A. List of Peptide Bulk Drug Substances Addressed by HHS Interim Enforcement Policy Regarding 503A Compounding 1. BPC-157 2. Epitalon 3. KPV 4. MOTS-c 5. Semax 6. TB-500”
FDA interim 503A bulks policy: a substance outside Category 1 gets no interim enforcement discretion
“Drug products compounded using a bulk drug substance for which each of the above circumstances are not present are not within the scope of the policy described in this guidance.”
For outsourcing facilities (section 503B)
Not on the 503B bulks list and not in any 503B category (FDA's 503B nominations list, updated March 21, 2025, does not name it)
“Outsourcing facilities, which operate under section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), may not compound a drug product that includes a bulk drug substance unless: The bulk drug substance appears on a list identifying bulk drug substances for which there is a clinical need (the 503B bulks list), or”
The 503B bulks list holds five substances (diphenylcyclopropenone, glycolic acid, quinacrine HCl oral, squaric acid dibutyl ester, trichloroacetic acid); none of the compounds in this file
“FDA has evaluated the following bulk drug substances and determined that there is a clinical need for outsourcing facilities to compound drug products using these bulk drug substances under section 503B of the FD&C Act:”
The FDA's compounding advisory committee
24 July 2026: Should emideltide (free base) and emideltide acetate be placed on the 503A bulks list? (uses FDA reviewed: opioid withdrawal, chronic insomnia and narcolepsy). Vote: 6 yes, 7 no, 1 abstention (both forms), per law-firm reports. Committee recommended against inclusion; no FDA rule; not in the HHS interim policy
“VOTE: Should Emideltide (free base) be placed on the list? ... VOTE: Should Emideltide acetate be placed on the list?”
Our reading
There is no current route to lawful 503A or 503B compounding of DSIP.
Every source above was checked again on 14 November 2026.
What 17 clinics charge
- FormBlendsDSIP injection (5mg)$161.10/mo
- Biotech LifestyleDSIP injectionfrom $179/mo
- Bowery ClinicDSIP capsules (500mcg)$199for 30 days
- Regenerative RevivalDSIP injection (1mg/ml)$199/mo
- Platform HealthDSIP injection (1mg/ml)$219/mo
What DSIP is
- What it is
- Neuropeptide
- How it works
- A nine-amino-acid peptide first isolated in studies of sleep.
- How it is given
- Subcutaneous injection
- Also called
- delta sleep-inducing peptide
DSIP side by side
About DSIP
Is DSIP FDA-approved?
No. No FDA-approved drug contains DSIP. What clinics sell is compounded by a pharmacy for a prescription, and the FDA does not review compounded products before they are sold.
Is DSIP legal in the US?
Whether a pharmacy may compound it for your prescription is what decides it. No FDA-approved drug contains DSIP (emideltide). FDA had it in 503A Category 2 from September 2023 until April 22, 2026 (nominations withdrawn). On July 24, 2026 the advisory committee voted 6-7 (1 abstention, per law-firm reports) against listing it, the only one of seven peptides that day it did not recommend. HHS left it out of its October 2026 interim policy. It is not on the 503A or 503B bulks list and is in no category.
How much does DSIP cost?
17 clinics publish a price. The lowest that compares per month is $161.10/mo at FormBlends, and the middle of 10 clinics' lowest monthly prices is about $224. What a month buys differs by clinic, so each price lists what it includes. every DSIP price
What forms does DSIP come in?
Clinics sell it as injection (14 prices), nasal spray (2 prices), capsules (1 price), other (1 price).